It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Atopic dermatitis (AD) is a chronic, allergic inflammatory skin disorder that lacks a definite cure. Using a mouse DNCB-induced AD-like skin lesions model, this study evaluated the potential therapeutic utility of tHGA as an oral and topical treatment for AD. Male BALB/c mice were sensitised and challenged with 1% and 0.5% DNCB on their shaved dorsal skin. Mice in the treatment group were administered tHGA (20, 40, and 80 mg/kg) orally three times per week for 2 weeks, or tHGA (0.2%, 1%, and 5%) topically once daily for 12 days. On day 34, the mice were euthanized, and blood and dorsal skin samples were obtained for analysis. All doses of orally and topically administered tHGA significantly improved scratching, epidermal thickness, blood eosinophilia and mast cell infiltration. There was a minor discrepancy between the two routes of administration, with orally treated tHGA showing significant reductions in Scoring of Atopic Dermatitis (SCORAD), tissue eosinophil infiltration, serum IgE and skin IL-4 levels with treatment of 40 and 80 mg/kg tHGA, whereas topically applied tHGA showed significant reductions in all dosages. These findings suggest that tHGA exhibited therapeutic potential for AD as both oral and topical treatment ameliorates AD-like symptoms in the murine model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X)
2 UCSI University, Faculty of Applied Sciences, Kuala Lumpur, Malaysia (GRID:grid.444472.5) (ISNI:0000 0004 1756 3061)
3 Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X); Pantai Hospital Kuala Lumpur, Premier Integrated Labs Sdn Bhd, Kuala Lumpur, Malaysia (GRID:grid.412516.5) (ISNI:0000 0004 0621 7139)
4 Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X); Universiti Putra Malaysia, Institute of Bioscience, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X)
5 Universiti Putra Malaysia, Faculty of Science, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X); Universiti Putra Malaysia, Institute of Bioscience, Serdang, Malaysia (GRID:grid.11142.37) (ISNI:0000 0001 2231 800X)
6 Monash University Malaysia, School of Science, Subang Jaya, Malaysia (GRID:grid.440425.3)
7 UCSI University, Faculty of Pharmaceutical Sciences, Kuala Lumpur, Malaysia (GRID:grid.444472.5) (ISNI:0000 0004 1756 3061); National Taiwan University, Graduate Institute of Pharmacology, College of Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241); UCSI University, UCSI Wellbeing Research Centre, Kuala Lumpur, Malaysia (GRID:grid.444472.5) (ISNI:0000 0004 1756 3061)